ClinicalTrials.gov
ClinicalTrials.gov Menu

The Use of Bupivacaine and Ropivacaine for Sciatic Nerve Block

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01272921
Recruitment Status : Completed
First Posted : January 10, 2011
Results First Posted : March 21, 2014
Last Update Posted : April 6, 2017
Sponsor:
Information provided by (Responsible Party):
Antoun Nader, Northwestern University

Brief Summary:
The duration of motor block for infragluteal parabiceps sciatic nerve block following total knee replacement may vary between 12-36 hrs depending on the amount of local anesthetic given.

Condition or disease Intervention/treatment Phase
The Duration of Motor Block May Vary Between 12-36 Hrs Drug: Bupivacaine Drug: Ropivacaine Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 142 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: A Dose Response Study for Duration of Analgesia Using Bupivacaine and Ropivacaine for Infragluteal Parabiceps Sciatic Block
Study Start Date : November 2010
Actual Primary Completion Date : August 2012

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Bupivacaine
Varying does to determine duration of analgesia following a sciatic nerve block
Drug: Bupivacaine
Varying doses to determine the duration of analgesia

Active Comparator: Ropivacaine
Varying does to determine duration of analgesia following a sciatic nerve block
Drug: Ropivacaine
Varying doses to determine the duration of analgesia




Primary Outcome Measures :
  1. Duration of Motor and Sensory Block of the Sciatic With 0.5% Bupivacaine and Ropivacaine After Ultrasound-guided Nerve-stimulator-Assisted Needle Positioning Beneath the CIEL [ Time Frame: 3 days ]
    Subject reported and investigator measured motor and sensory blockade of the sciatic nerve with less than 10ml of 0.5% bupivacaine and ropivacaine after ultrasound-guided nerve-stimulator-assisted needle positioning beneath the common investing external layer (CIEL).


Secondary Outcome Measures :
  1. Cumulative Probabilities for Needle Positioning Above and Below CIEL. [ Time Frame: 1 Day ]
    The cumulative probability distributions for the minimal current to evoke a motor response with the needle tip positioned external (above) to the common investing extraneural layer (CIEL) and the cumulative probability distribution for the needle tip postioned internal (below) to the CIEL were sought. The difference in the mean minimum threshold current (mA) for the external (above) and internal (below) CIEL positioning were calculated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients (>18 years of age) who are undergoing elective total knee arthroplasty will be included in the study.

Exclusion Criteria:

  • Exclusion criteria for the study are patient refusal to be included in the study, contraindications to regional anesthesia, history of allergy to amide local anesthetics, the presence of a progressive neurological deficit, the presence of coagulopathy or infection, or pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01272921


Locations
United States, Illinois
Northwestern University, Feingberg School of Medicine
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern University
Investigators
Principal Investigator: Antoun Nader, MD Northwestern University Feinberg School of Medicine

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Antoun Nader, Professor in Anesthesiology and Orthopaedic Surgery, Northwestern University
ClinicalTrials.gov Identifier: NCT01272921     History of Changes
Other Study ID Numbers: STU00035380
First Posted: January 10, 2011    Key Record Dates
Results First Posted: March 21, 2014
Last Update Posted: April 6, 2017
Last Verified: March 2017

Additional relevant MeSH terms:
Bupivacaine
Ropivacaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents